November 14th 2024
CARE – Infographic – Work Package 7 – Clinical evaluation of repurposed or novel SARS-CoV-2 antivirals or antibodies
CARE – Infographic - Work Package 7 - Clinical evaluation of repurposed or novel SARS-CoV-2 antivirals or antibodies CARE has 8 Work Packages but do you know what each one does? Here, you can learn about the Work Package 7 team, their objectives, their partners, their breakthrough moments and more. The infographic is also available [...]
Read more
November 7th 2024
Publication in Antiviral Research: Combining of Remdesivir, Molnupiravir and Ribavirin inhibits coronavirus replication
Publication in Antiviral Research: Combining of Remdesivir, Molnupiravir and Ribavirin inhibits coronavirus replication Further to CARE'S SARS-CoV-2 research, CARE partner KU Leuven has explored the inhibitory effect of a combination of 3 broad-spectrum antiviral nucleosides on the replication of coronaviruses as demonstrated through experiments with infected primary human airway epithelial cell (HAEC) cultures and subsequently [...]
Read more
October 31st 2024
The COVID-19 QTL-GWAS colocalization explorer application – allowing easy query of summary statistics and visualization of the genomic context of significant COVID-19 gene links
The COVID-19 QTL-GWAS colocalization explorer application - allowing easy query of summary statistics and visualization of the genomic context of significant COVID-19 gene links With the aim of understanding host response and prioritising treatment targets, the CARE partner AbbVie sought to identify human genes influencing genetically driven disease risk and severity, and to identify additional [...]
Read more
October 24th 2024
A picture paints a thousand words: Utrecht University expertise in Cryo-EM technology continues to bring benefit to CARE’s small molecule and antibody development work
Dr. Daniel Hurdiss, Assistant Professor, Utrecht University Cryogenic electron microscopy (cryo-EM) capability has been made available to CARE through the expertise of CARE partner, Utrecht University (UU). Virologists from UU’s Biomolecular Health Sciences department use cryo-EM as one of their core techniques to study viruses, under the leadership of Dr. Daniel Hurdiss who has used [...]
Read more
October 17th 2024
Published in PLoS Pathogens: picornaviruses modulate nucleotide metabolism
Published in PLoS Pathogens: picornaviruses modulate nucleotide metabolism The CARE partner Utrecht University (UU) assessed the modulation of host metabolism by two picornaviruses using steady state as well as 13C-glucose tracing metabolomics. The family Picornaviridae, a large family of small, non-enveloped viruses with a single stranded positive sense RNA genome, includes many well-known human and [...]
Read more
October 10th 2024
CARE – Infographic – Work Package 6 – From lead to pre-clinical candidate and proof-of-concept in small-animal and non-human primate models
CARE – Infographic - Work Package 6 - From lead to pre-clinical candidate and proof-of-concept in small-animal and non-human primate models CARE has 8 Work Packages but do you know what each one does? Here, you can learn about the Work Package 6 team, their objectives, their partners, their breakthrough moments and more. The infographic [...]
Read more
October 3rd 2024
Published in MCP: Assessment of Kinome-Wide Activity Remodeling upon Picornavirus Infection
Published in MCP: Assessment of Kinome-Wide Activity Remodeling upon Picornavirus Infection The CARE partner Utrecht University (UU) conducted an overview of the (de)regulation of kinase activities (kinome) by two picornaviruses during infection using a targeted mass spectrometry-based system-wide kinase activation assay (covering ~40% of the human kinome). The family Picornaviridae, a large family of small, [...]
Read more
September 26th 2024
CARE’s Young Researcher – Oliver Debski-Antoniak
CARE’s Young Researchers – Introducing Oliver Debski-Antoniak PhD, Utrecht University Read about how Oliver’s work in the discovery and advancement of potential antibody treatments for both existing and emerging coronavirus infections is making a significant contribution towards efforts in prevention and alleviation of economic and health strains caused by endemics and pandemics in the future. CARE [...]
Read more
September 19th 2024
Published in Nature: First insights into the Porcine Deltacoronavirus spike
Published in Nature: First insights into the Porcine Deltacoronavirus spike Further to CARE’s SARS-CoV-2 research, CARE partner Utrecht University (UU) has studied the Porcine Deltacoronavirus (PDCoV) spike, providing crucial insights for developing antiviral strategies. PDCoV, an emerging enteric pathogen in pigs, has recently been detected in children with acute febrile illness. PDCoV enters cells by [...]
Read more
September 12th 2024
CARE – Infographic – Work Package 5 – identifying immune markers contributing to the host immune responses to SARS-CoV-2 infection and their correlations with clinical and virological outcomes
CARE – Infographic - Work Package 5 - identifying immune markers contributing to the host immune responses to SARS-CoV-2 infection and their correlations with clinical and virological outcomes CARE has 8 Work Packages but do you know what each one does? Here, you can learn about the Work Package 5 team, their objectives, their partners, [...]
Read more
September 5th 2024
CARE’s Young Researcher – Manon Laporte
CARE’s Young Researchers – Introducing Manon Laporte, PhD, KU Leuven Read about how Manon’s work in phenotypic antiviral screening enabled the discovery of a novel target in the replication cycle of coronaviruses and a small molecule inhibitor that can address that target, plus how this approach may benefit future pandemic preparedness across many virus types. [...]
Read more
August 1st 2024
CARE – Infographic – Work Package 4 – Generation and characterisation of monoclonal antibodies against SARS-CoV-2 and related coronaviruses
CARE – Infographic - Work Package 4 - Generation and characterisation of monoclonal antibodies against SARS-CoV-2 and related coronaviruses CARE has 8 Work Packages but do you know what each one does? Here, you can learn about the Work Package 4 team, their objectives, their partners, their breakthrough moments and more. The infographic is also [...]
Read more
July 25th 2024
CARE’s Young Researcher – Holly Kerr
CARE’s Young Researchers – Introducing Holly Kerr, PhD, University of Edinburgh Read about how Holly’s work in getting a better understanding of host response and resulting disease may help identify alternative or complementary approaches to direct-acting anti-virals by targeting the host. CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the [...]
Read more
July 18th 2024
Introducing NUVISAN – a CARE Industry organisation
Introducing NUVISAN – a CARE Industry organisation Founded in Europe in 1989 as an independent, family-owned contract research organization (CRO), NUVISAN was set up with a clear purpose: to leverage science to foster positive change and enhance the lives of patients. Initially providing bioanalytical laboratory services and PK/PD studies, the company later expanded to other [...]
Read more
July 11th 2024
CARE – Infographic – Work Package 3 Antiviral drug development: Hits to Leads
CARE – Infographic - Work Package 3 Antiviral Drug Development: Hits to Leads. CARE has 8 Work Packages but do you know what each one does? Here, you can learn about the Work Package 3 team, their objectives, their partners, their breakthrough moments and more. The infographic is also available here
Read more
July 4th 2024
Published in Antiviral Research: A new fully automated dual-reporter HTS antiviral assay to facilitate drug discovery against SARS-CoV-2
Published in Antiviral Research: A new fully automated dual-reporter HTS antiviral assay to facilitate drug discovery against SARS-CoV-2. CARE partner KU Leuven developed a dual-reporter high-throughput screening (HTS) assay to facilitate antiviral drug discovery against SARS-CoV-2 using a fully automated, high-containment robot system. For this purpose, by clonal selection, KU Leuven successfully obtained an A549 [...]
Read more
June 27th 2024
CARE 4th External Newsletter is now available
CARE External Newsletter - June 2024 The new issue of our biannual newsletter is out. In this edition we learn about cryo-EM and how this exciting new technology is benefiting our scientific endeavours across CARE, plus we introduce 3 CARE partners: Utrecht University and the Institute for Virology and Immunology (academic organisations) and Nuvisan (industry [...]
Read more
June 20th 2024
CARE’s Young Researcher -Thijs Steijaert
CARE’s Young Researchers – Introducing Thijs Steijaert, PhD student, Leiden University Medical Centre Meet Thijs! Thijs Steijaert is a PhD student at Leiden University Medical Centre and in this short video, describes for us his role in CARE Work Package 5, where his work is contributing to growing scientific knowledge of our understanding of host [...]
Read more
June 13th 2024
CARE – Infographic: Work Package 2 Target-based drug discovery and design
CARE – Infographic: Work Package 2 Target-based drug discovery and design. CARE has 8 Work Packages but do you know what each one does? Here, you can learn about the Work Package 2 team, their objectives, their partners, their breakthrough moments and more. The infographic is also available here
Read more
June 6th 2024
Published in Viruses: Lower infectivity of recent SARS-CoV-2 omicron sub–variants in Syrian Hamster
Published in Viruses: Lower infectivity of recent SARS-CoV-2 omicron sub–variants in Syrian Hamster. The CARE partner, KU Leuven (KUL) evaluated the infectivity of two important sub-variants of omicron in Syrian hamsters. Indeed, since the emergence of the first omicron SARS-CoV-2 variant at the end of 2021, several sub-variants have evolved and become predominant in the [...]
Read more
May 30th 2024
CARE’s Young Researcher – Wenjuan Du
CARE’s Young Researchers – Introducing Wenjuan Du, Post-doctoral researcher, Utrecht University Read about how Collins’s work in understanding how the coronavirus hijacks human host factors and processes has provided us with opportunities to develop therapies to inhibit viral replication. CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. [...]
Read more
May 23rd 2024
Published in Viruses: CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses
Published in Viruses: CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses The CARE member, Centre Hospitalier Universitaire Vaudois (CHUV), has published a paper on the differences observed between hospitalised and non-hospitalised patients following SARS-CoV-2 infection in terms of the levels of detectable anti-SARS-CoV-2 neutralising responses and [...]
Read more
May 16th 2024
CARE’s Young Researcher – Collins Owino
CARE’s Young Researchers – Introducing Collins Owino, Post-doctoral researcher, Utrecht University Read about how Collins’s work in understanding how the coronavirus hijacks human host factors and processes has provided us with opportunities to develop therapies to inhibit viral replication. CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. [...]
Read more
May 9th 2024
CARE – Infographic: Work Package 1 anti-coronavirusdrug discovery in phenotypic virus-cell-based assays
CARE – Infographic: Work Package 1 Anti-coronavirus drug discovery in phenotypic virus-cell-based assays. CARE has 8 Work Packages but do you know what each one does? Here, you can learn about the Work Package 1 team, their objectives, their partners, their breakthrough moments and more. The infographic is also available here
Read more
May 2nd 2024
CARE – Infographic: Research objectives and operating model
CARE – Infographic: Research objectives and Operating model Do you whish to know what we do and how we do it? Check out this infographic for key details on CARE Research objectives and Operating model. The infographic is also available here
Read more
April 25th 2024
Published in Antiviral Res: A new image-based and high-throughput platform to identify broad-spectrum coronavirus antivirals
Published in Antiviral Res: A new image-based and high-throughput platform to identify broad-spectrum coronavirus antivirals The CARE member, Johnson & Johnson Innovative Medicine, developed a high-content imaging platform compatible with high-throughput screening, with the aim of identifying compounds with antiviral activity and to deprioritize those that induce undesirable phenotypes in host cells. The immunofluorescence-based assay [...]
Read more
April 18th 2024
Introducing Utrecht University – a CARE academic organisation
Introducing Utrecht University – a CARE academic organisation Established in 1636, Utrecht University has a long history and is rich in tradition. Utrecht University was formed by the provincial government in 1636. Recognized as the leading Dutch university according to the Shanghai Ranking, it offers 45 undergraduate and 167 graduate programs, has some 30,000 students [...]
Read more
April 11th 2024
CARE Partner perspectives – Frank van Kuppeveld
CARE Partner perspectives - Frank van Kuppeveld The Covid-19 pandemic is over so what is the value of CARE? Principal investigators comment on CARE's importance for future pandemic preparedness. Today, see the response from Prof. Dr. Frank van Kuppeveld, head of the Virology Division of the Faculty of Veterinary Medicine at Utrecht University.
Read more
April 4th 2024
CARE – Infographic: Leadership and partnership
CARE – Infographic: Leadership and partnership Do you whish to know who are particpating in this concortium and who are leading it? Check out this infographic for key details on CARE partnership. The infographic is also available here
Read more
March 28th 2024
Introducing The Institute of Virology and Immunology (IVI) – a CARE academic organisation
Introducing The Institute of Virology and Immunology (IVI) – a CARE academic organisation In 1917, Swiss laws on epizootics were drawn up to combat foot-and-mouth disease effectively. In response, the Swiss Confederation built the Federal Vaccine Institution in 1942. In 1992, the institute was renamed to Institute of Virology and Immunoprophylaxis and moved to a [...]
Read more
March 21st 2024
CARE Partner perspectives – Rob Jordan
CARE Partner perspectives - Rob Jordan The Covid-19 pandemic is over so what is the value of CARE? Principal investigators comment on CARE's importance for future pandemic preparedness. Today, see the response from Rob Jordan, Senior Program Officer at the Bill & Melinda Gates Foundation.
Read more
March 14th 2024
Successful CARE 4th Annual meeting
Succesful CARE 4th Annual meeting We just finished a super exciting 4th CARE annual meeting in Leiden, Netherlands. Many thanks to the organizers from LUMC and Inserm Transfert, as well as to all participants for their great presentations and captivating discussions – this will inspire further acceleration of our most promising assets and research projects which [...]
Read more
March 7th 2024
CARE convenes for its 4th Annual meeting on March 12-13
CARE convenes for its 4th Annual meeting on March 12-13 What happened in CARE in the past few months? The CARE partners will have the opportunity to discover and discuss the latest news, endeavours and achievements in the upcoming annual meeting (already the fourth one) that will be held in Leiden, NL, on March 12-13. [...]
Read more
February 29th 2024
CARE Partner perspectives – Yves Lévy
CARE Partner perspectives - Yves Lévy The Covid-19 pandemic is over so what is the value of CARE? Principal investigators comment on CARE's importance for future pandemic preparedness. Today, see the response from Yves Lévy, Inserm-Vaccine Research Institute, academic coordinator of CARE.
Read more
February 22nd 2024
CARE Partner perspectives – Cyril Dousson
CARE Partner perspectives - Cyril Dousson The Covid-19 pandemic is over so what is the value of CARE? Principal investigators comment on CARE's importance for future pandemic preparedness. Today, see the response from Cyril Dousson, CEO of Ai-biopharma.
Read more
February 15th 2024
CARE – Infographic: What is CARE?
CARE – Infographic: What is CARE? Do you need a quick overview of CARE? Check out this infographic for the key details of CARE at a glance. The infographic is also available here
Read more
February 8th 2024
The faces behind the CARE work-packages – Panthéa Tzourio, WP8 Task Lead
The faces behind the CARE work-packages - Panthéa Tzourio, WP8 Task Lead CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 38 partners’ shared key goals: (1) to identify therapeutics [...]
Read more
February 1st 2024
The faces behind the CARE work-packages – Craig Fenwick, WP4 academic Lead
The faces behind the CARE work-packages - Craig Fenwick, WP4 academic Lead CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 38 partners’ shared key goals: (1) to identify therapeutics [...]
Read more
January 25th 2024
The faces behind the CARE work-packages – Richard Zwaal, WP1 EFPIA Lead
The faces behind the CARE work-packages - Richard Zwaal, WP1 EFPIA Lead CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 38 partners’ shared key goals: (1) to identify therapeutics [...]
Read more
January 18th 2024
New potent bisubtrate inhibitors of SARS-CoV-2 nsp14 N7-Methyltransferase
New potent bisubtrate inhibitors of SARS-CoV-2 nsp14 N7-Methyltransferase The CARE partner Aix-Marseille University (AMU), in collaboration with other research groups, has published two articles pertaining to the development of new bisubstrate inhibitors against the SARS-CoV-2 nsp14 (N7-guanine)-methyltransferase (N7-MTase). This enzyme, which catalyses the transfer of the methyl group from the S-adenosyl-L-methionine (SAM) cofactor to the [...]
Read more
January 11th 2024
Preparing for future pandemics: outputs and progress resulting from a European Commission sponsored workshop in November 2022
Preparing for future pandemic: outputs and progress resulting from a European Commission (EC) sponsored workshop in November 2022 While Covid-19 is no longer deemed to be a pandemic, the risk of future pandemics remains. Application of lessons learned during our collective recent experience is vital to being in a stronger position to handle this situation [...]
Read more
December 20th 2023
CARE 3rd External Newsletter is now available
CARE External Newsletter - December 2023 The new issue of our biannual newsletter is out. In this edition, we share the EC sponsored recommendations about pandemic preparedness and we introduce 2 CARE partners, i.e., Iktos, a SME, and LUMC, an academic organisation. Read the Newsletter here: CARE External Newsletter - December 2023
Read more
November 30th 2023
Published in Journal of infection: a new potent, broad-spectrum antibody isolated
Published in Journal of infection: a new potent, broad-spectrum antibody isolated The CARE partner Centre Hospitalier Universitaire Vaudois (CHUV) isolated a broad-spectrum monoclonal antibody (mAb), named P4J15, which showed neutralizing activity against all variants including the latest XBB.2.3 and EG.5.1 sub-lineages, against which all authorized therapeutic mAbs have become almost completely ineffective. The collaboration within [...]
Read more
November 23rd 2023
Introducing Iktos – a CARE SME organisation
Introducing Iktos – a CARE SME organisation Iktos was founded in 2016 by Yann Gaston-Mathé, Quentin Perron and Nicolas Do Huu, to develop an innovative and user-friendly technology platform for deep learning-based de novo drug design, leveraging a proprietary algorithm developed by Quentin and Nicolas Iktos is an innovative company specializing in the development of [...]
Read more
November 16th 2023
Introducing Ai-biopharma – a CARE SME organisation
Introducing Ai-biopharma – a CARE SME organisation Ai-biopharma was set up in 2018 by Dr Cyril B. Dousson. It is a Biopharma company which specializes in research into medicinal chemistry of preclinical drug candidates, based in France. Ai-biopharma is an early-stage small molecule drug discovery company advancing its antiviral programmes based on a proprietary Chemoinformatic [...]
Read more
November 9th 2023
Introducing Leiden University Medical Center – a CARE academic organisation
Introducing Leiden University Medical Center – a CARE academic organisation The LUMC has a long history and has its origins in the 16th century when in 1575, following a year-long siege, William of Orange granted Leiden the right to have a university. The university started with 3 faculties: Law, Theology and Medicine. In 1996, the Leiden University [...]
Read more
November 2nd 2023
Inserm VRI-led research reveals predictors of severe disease and long COVID symptoms
Inserm VRI-led research reveals predictors of severe disease and long COVID symptoms The CARE partner Inserm-VRI has recently published two articles pertaining to severe SARS-CoV-2 infected patients from the French COVID cohort. The first article delves into the severity of SARS-CoV2 infection, to identify markers associated with the extent of severity of SARS-CoV2 infection. The [...]
Read more
October 31st 2023
One new deliverable available on CARE website
One new CARE deliverable is now publicly available on CARE webpage “Resources“ How far has CARE progressed with its anti-coronavirus small molecule development? Read about screening cascades for hit discovery and the hit development programmes currently ongoing in CARE in the latest Portfolio report (D3.12).
Read more
October 26th 2023
CARE latest annual project summary available
CARE latest annual project summary is now publicly available on CARE webpage “Resources“ Do you wish to know more about the progress made by the CARE project? Read the summary for the third year of the project, presenting CARE’s main results achieved after three year of research (March 2023).
Read more
October 19th 2023
About CARE’S Scientific and Ethics Advisory Board
About CARE’S Scientific and Ethics Advisory Board What is the SEAB? SEAB stands for Scientific and Ethics Advisory Board. It is an independent group, appointed by the CARE Steering Committee (SCOM) that can provide objective feedback on the activities and plans of the consortium in order to ensure its obligations are fulfilled. Who is [...]
Read more
October 12th 2023
An overview of SCORE – a small EU-funded consortium with many connections to CARE
SCORE (Swift COronavirus Therapeutics REsponse), a small EU-funded consortium of 8 partner organisations who also contribute to CARE, has successfully delivered pre-clinical proof of concept in six potential assets, published 40 papers to disseminate findings, and built a valuable SARS-CoV-2 specific toolset to aid further research Within the 30-month timeframe of the project, under the leadership of [...]
Read more
October 5th 2023
CARE’s Young Researcher – Emmely Treffers
CARE’s Young Researchers – Introducing Emmely Treffers, Postdoctoral Researcher, LUMC Read about how Emmely’s work in proteomics of SARS-CoV-2 infected systems is growing our knowledge of how virus and host interact, in order to find novel ways to disrupt viral life cycle or counteract potential pathogenic host responses. CARE (Corona Accelerated R&D in Europe) is [...]
Read more
September 28th 2023
CARE’s Young Researcher – Grace Beirne
CARE’s Young Researchers – Introducing Grace Beirne, PhD student, KU Leuven Read about how Grace’s work in System Dynamics Modelling will help optimize the set-up of future consortia CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It comprises 38 partners, from both industry and academia, in a [...]
Read more
September 21st 2023
CARE – Committed to the COVID-19 cause
CARE - Committed to the COVID-19 cause In May 2023, the World Health Organisation announced that the COVID-19 pandemic “is now an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC)”, so should we still CARE? When CARE was initiated, the world was reacting to a rising [...]
Read more
September 14th 2023
CARE presentation at 9th ESWI Influenza conference in Valencia
CARE presentation at 9th ESWI Influenza conference in Valencia Are you going to the 9th ESWI Influenza conference in Valencia next week? If so, you will have the opportunity to learn about a new SARS-CoV-2 inhibitor that is targeting the membrane protein. Do not hesitate to attend this presentation by CARE partner KU Leuven. Title [...]
Read more
July 6th 2023
Published in Frontiers in Medicine: The application of data altruism in clinical research through empirical and legal analysis lenses
Published in Frontiers in Medicine: The application of data altruism in clinical research through empirical and legal analysis lenses The CARE partner KU Leuven has worked with clinical research stakeholders to understand their views and gain insights into the legal ramifications of the recently introduced concept of data altruism. This novel mechanism was introduced by [...]
Read more
June 30th 2023
CARE 2nd External Newsletter is now available
CARE External Newsletter - June 2023 The new issue of our biannual newsletter is out. In this edition, you can learn about the value CARE is bringing in the light of the changing status of the pandemic; some interesting research into Post-COVID Condition (aka Long COVID); a profile of CARE partner #Ai-biopharma, and a summary [...]
Read more
June 21st 2023
Published in PNAS: A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein
Published in PNAS: A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein The CARE partner Utrecht University, in collaboration with other research groups, has developed a spike-targeting macrocyclic peptide that demonstrated inhibition of SARS-CoV-2 infection. Structural, functional and bioinformatic analysis revealed the details of a conserved quaternary binding site. Consistent with this, the cyclic [...]
Read more
June 8th 2023
Successful CARE 3rd Annual meeting
Succesful CARE 3rd Annual meeting We just finished a super exciting 3rd CARE annual meeting in Leuven, Belgium. Many thanks to the organizers from KUL and all participants for their great presentations and captivating discussions – this will inspire further acceleration of our most promising assets and research projects and help us to best react [...]
Read more
June 1st 2023
CARE is meeting for its 3rd Annual meeting on June 6-7
CARE is meeting for its 3rd Annual meeting on June 6-7 CARE consortium eagerly awaits its third, in person annual meeting on 6-7 June 2023 in Leuven, Belgium. With all other interactions between the 38 partners taking place virtually, this annual event is a welcome opportunity for showcasing endeavours and achievements, as well as enabling [...]
Read more
May 25th 2023
Published in J Clin Immunol: Persistence of abnormalities in the blood of convalescent COVID-19 patients until 6 months after hospital discharge
Published in J Clin Immunol: Persistence of abnormalities in the blood of convalescent COVID-19 patients until 6 months after hospital discharge The CARE partner Inserm-VRI (France), in collaboration with the Centre Hospitalier Universitaire Vaudois (CHUV, Switzerland) has found persistent abnormalities in the blood of convalescent severe COVID-19 subjects up to six months after leaving the [...]
Read more
May 18th 2023
Published in Microorganisms: Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses
Published in Microorganisms: Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses The CARE partner Janssen Pharmaceutica in collaboration with University Utrecht, KU Leuven and Goethe University Frankfurt has published a paper about the discovery of a small molecule, Z-Tyr-Ala-CHN2, which was identified in a cell-based antiviral screen. The molecule exerts sub-micromolar antiviral [...]
Read more
May 11th 2023
CARE presentation at at 19th Annual PEGS Boston conference and expo
CARE presentation at 19th Annual PEGS Boston conference and expo Are you going to the 19th Annual PEGS Boston conference & Expo: The Essential Protein Engineering and Cell Therapy Summit next week? If so, you will have the opportunity to discover how to identify pre-lead antibodies that have multiple epitopes on the SARS-CoV-2 spike protein [...]
Read more
May 4th 2023
Published in Antiviral Res: A VeroE6 cell line not requiring Pgp inhibitors to evaluate SARS-CoV-2 antivirals
Published in Antiviral Res: A VeroE6 cell line not requiring Pgp inhibitors to evaluate SARS-CoV-2 antivirals Cell culture virus replication systems are essential for the study of virus replication and pathogenesis, antiviral drug testing, and virus research. Vero cells are one of the cell lines used for drug discovery as they are susceptible to SARS-CoV-2 [...]
Read more
April 27th 2023
Published in iScience: A new optimized SARS-CoV-2 phenotypic screening platform
Published in iScience: A new optimized SARS-CoV-2 phenotypic screening platform The CARE partner Goethe University Frankfurt Institute of Medical Virology, published a paper reporting on a novel phenotypic screening platform for the identification of drug candidates with activity against SARS-CoV-2 and other coronaviruses. This successful proof of concept was based on the determination of caspase [...]
Read more
April 20th 2023
Published in Journal of Virology: A new mouse model for preclinical evaluation of potential antivirals
Published in in Journal of Virology: A new mouse model for preclinical evaluation of potential antivirals As ancestral SARS-CoV-2 viruses are not able to bind to the mouse ACE2 receptor, establishment of SARS-CoV-2 mouse models has been limited to the use of mouse-adapted viruses or genetically modified mice. In parallel, Syrian hamsters are considered one [...]
Read more
April 13th 2023
Published in Frontiers in Pharmacology: Combination of antiviral drugs proved to be more efficient than monotherapy
Published in Frontiers in Pharmacology: Combination of antiviral drugs proved to be more efficient than monotherapy Combinations of antiviral drugs result in improved potency and help to avoid or delay the development of resistant variants in some infectious disease (such as HIV and hepatitis C). From this perspective, CARE partner KU Leuven (KUL, Belgium) explored [...]
Read more
March 10th 2023
CARE presentation at ICAR2023
CARE presentation at ICAR2023 Are you going to ICAR2023 in Lyon in March? If so, you will get the opportunity to hear about a novel SARS-CoV-2 inhibitor discovered and characterized as part of the H2020 project SCORE and IMI project CARE on Wednesday 15 March. Title of the presentation: A novel SARS-CoV-2 inhibitor with potent [...]
Read more
February 23rd 2023
The faces behind the CARE work-packages – WP7
The faces behind the CARE work-packages - WP7 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
February 9th 2023
FAIRplus and CARE collaboration to publish FAIR SARS-CoV-2 data
FAIRplus and CARE collaboration to publish FAIR SARS-CoV-2 data Publishing datasets in the public domain is important to avoid the duplication of research. For effective dissemination, it is important for the datasets to be FAIR, i.e., Findable, Accessible, Interoperable and Reusable. The IMI FAIRplus project, whose purpose was to develop tools and guidelines for making [...]
Read more
February 1st 2023
Iktos, a new CARE partner
Iktos, a new partner of CARE consortium CARE is welcoming Iktos as a new consortium member. Iktos is developing artificial intelligence solutions for medicinal chemistry and new drug design. Iktos will contribute to CARE by building in silico models predicting molecule activity in biological assays and designing molecules with predicted profile converging towards the desired [...]
Read more
January 30th 2023
Follow us on LinkedIn!
Follow us on LinkedIn! CARE is now on LinkedIn. Click here to connect with us and get up to date information on the CARE project.
Read more
December 22nd 2022
Published in Frontiers in Medicine: the COVID-19 pandemic hampered the sharing of information with and securing of consent from clinical study participants, but did not impact GDPR compliance
Published in Frontiers in Medicine: the COVID-19 pandemic hampered the sharing of information with and securing of consent from clinical study participants, but did not impact GDPR compliance CARE partner KU Leuven (KUL, Belgium) conducted an online survey followed by semistructured interviews to gain insights into compliance with the General Data Protection Regulation (GDPR) for [...]
Read more
December 20th 2022
Published in Structure: An insight into nsp10-mediated modulation of nsp14 exonuclease activity
Published in Structure: An insight into nsp10-mediated modulation of nsp14 exonuclease activity The CARE partners Jagiellonian University (JU, Poland) and the Universty of Dundee (UnivDun, UK) discovered a key component of the regulation of nsp14 exonuclease activity by nsp10 using X-ray crystallography. During RNA replication, coronaviruses require proofreading to maintain the integrity of their large [...]
Read more
December 16th 2022
Published in Nature Micobiology: a new monoclonal antibody neutralizing SARS-CoV-2 Omicron variants
Published in Nature Micobiology: a new monoclonal antibody neutralizing SARS-CoV-2 Omicron variants The CARE partner Centre Hospitalier Universitaire Vaudois (CHUV) isolated a monoclonal antibody (mAb) named P2G3 that does not lose activity towards Omicron BA.1 and BA.2 compared to other variants of concern (VOC) (Wild Type, Alpha, Beta and Delta) and is more potent than [...]
Read more
December 15th 2022
CARE 1st External Newsletter is now available
CARE External Newsletter - December We are proud to announce the publication of CARE 1st External Newsletter. In this edition, you can learn about the CARE project, its collaborative culture and ways you may be able to contribute. Download the call for collaboration here: CARE External Newsletter - Dec 2022
Read more
December 13th 2022
Call for collaboration
Possible collaboration with IMI CARE for late phase development of SARS-CoV-2/pan coronavirus antivirals and antibodies. Have you developed a SARS-CoV-2 or potential broad-spectrum compound (small molecule or antibody) and need support with its characterisation, pre-clinical and/or early clinical testing? The CARE project has developed three platforms open to external collaboration to prepare the next generation [...]
Read more
November 29th 2022
Five new deliverables are now publicly available on CARE webpage “Resources”!
Five new deliverables are now publicly available on CARE webpage "Resources" Do you wish to be able to run an antiviral screen and toxicity counter screen in one test? Look at the deliverable D1.1 to learn about this dual reporter HTS assay, developed by engineering a host cell line and a virus to express each [...]
Read more
September 22nd 2022
The faces behind the CARE work-packages – WP6
The faces behind the CARE work-packages - WP6 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
August 2nd 2022
The faces behind the CARE work-packages – WP5
The faces behind the CARE work-packages - WP5 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
July 26th 2022
The faces behind the CARE work-packages – WP4
The faces behind the CARE work-packages - WP4 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
July 19th 2022
Published in eBioMedicine: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
Published in eBioMedicine: Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine The CARE partner Centre Institut National De La Santé Et De La Recherche Médicale – Vaccine Reserch Institute (INSERM-VRI) published a paper reporting on the design and testing of a protein subunit vaccine CD40.CoV2. The immunogenicity and antiviral efficacy of the vaccine [...]
Read more
July 12th 2022
Published in JAMA Oncology: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
Published in JAMA Oncology: Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients The CARE partner Centre Hospitalier Universitaire Vaudois (CHUV) in collaboration with Lausanne University Hospital published a paper reporting on the durability of neutralizing antibody responses elicited by messenger RNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) against the SARS-CoV-2 [...]
Read more
July 7th 2022
Published in MDPI: Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication
Published in MDPI: Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication The CARE partners Katholieke Universiteit Leuven (KUL), Universiteit Utrecht (UU), University Of Dundee (UNIVDUN), Universitaet Zu Luebeck (UZL) in collaboration with a number of other organisations published a paper reporting on the conduct of a high-throughput screening of a 160 K compound library against SARS-CoV-2, yielding [...]
Read more
July 5th 2022
Published in CellPress iScience: Computed Tomography and [18 F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates
Published in CellPress iScience: Computed Tomography and [18 F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates The CARE partners Institut National De La Santé Et De La Recherche Médicale – Vaccine Research Institute (INSERM-VRI) and Commissariat À L'énergie Atomique Et Aux Énergies Alternatives (CEA) published a paper reporting [...]
Read more
June 30th 2022
CARE 2nd Annual meeting
CARE 2nd Annual meeting CARE 2nd Annual meeting was successfully held in Paris on 9-10 June 2022, in presence of CARE Scientific and Ethics Advisory Board and IHI Project Officer. Around 60 people attended in person and 50 remotely to listen to and to discuss the project progress, achievements and next steps.
Read more
May 31st 2022
CARE paper published in Antiviral Research: Insight on the activity of Remdesivir, Molnupiravir and Nirmatrelvir on SARS-CoV-2 variants of concern
CARE paper published in Antiviral Research: Insight on the activity of Remdesivir, Molnupiravir and Nirmatrelvir on SARS-CoV-2 variants of concern The CARE partner KU Leuven, in collaboration with University Hospitals Leuven evaluated the susceptibility of SARS-CoV-2 variants to Remdesivir, Molnupiravir and Nirmatrelvir. The three molecules have in vitro antiviral activities against the ancestral virus as [...]
Read more
May 24th 2022
CARE paper published in Journal of Medical Virology: Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity
CARE paper published in Journal of Medical Virology: Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity The CARE partners KU Leuven and Janssen Pharmaceutica NV, in collaboration with The Institute of Medical Virology published a paper reporting on the outcomes from screening a library of antiviral compounds to assess effectiveness [...]
Read more
February 24th 2022
White paper published: High throughput cryo-electron microscopy epitope mapping of SARS-CoV-2 spike protein antibodies
High throughput cryo-electron microscopy epitope mapping of SARS-CoV-2 spike protein antibodies The CARE partners Takeda and Utrecht University, in collaboration with Thermo Fisher Scientific, published a white paper demonstrating how cryo-electron microscopy can be used as tool for high-throughput epitope mapping of antibodies that block SARS-CoV-2 virus entry. One of the main concerns of the [...]
Read more
February 21st 2022
Published in Nature Communications: Mechanism of AT-527 presents as a promising research avenue against COVID-19
Published in Nature Communications: Mechanism of AT-527 presents as a promising research avenue against COVID-19 A research group including the CARE partner Aix-Marseille University investigated the guanosine analogue AT-527 (Bemnifobuvir) using high-resolution cryo-electromicroscopy. Once in cells, AT-527 is converted into AT-9010that presumably has a dual mechanism of action (1) at the level of the viral [...]
Read more
February 14th 2022
The faces behind the CARE work-packages – WP3
The faces behind the CARE work-packages - WP3 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
January 10th 2022
The faces behind the CARE work-packages – WP2
The faces behind the CARE work-packages - WP2 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
December 13th 2021
The faces behind the CARE work-packages – WP1
The faces behind the CARE work-packages - WP1 CARE (Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. It is no surprise that it is designed in a comprehensive, yet agile, structure to fulfill the 37 partners’ shared key goals: (1) to identify therapeutics for the current pandemic, (2) to identify antiviral therapies for future outbreaks and (3) [...]
Read more
December 9th 2021
CARE paper published in JCIM: Modeling of protein-small molecule complexes with HADDOCK
CARE paper published in JCIM: Modeling of protein-small molecule complexes with HADDOCK CARE partners of the University of Utrecht studied the interactions between compounds and protein receptors using a new protocol in HADDOCK (High Ambiguity Driven DOCKing). Compound-protein interactions are a crucial task in drug discovery and HADDOCK is an integrative modeling platform which incorporates [...]
Read more
December 6th 2021
CARE paper published in Journal of Virology: New insights for assessment of SARS-CoV-2 infection estimates and (vaccine-induced) antibody durability response
CARE paper published in Journal of Virology: New insights for assessment of SARS-CoV-2 infection estimates and (vaccine-induced) antibody durability response CARE researchers have determined SARS-CoV-2-specific antibody responses to different proteins (trimeric spike protein, monomeric spike protein and nucleocapsid protein) in sera of people infected with COVID-19 in acute-infection and post-infection phases. The results suggest that [...]
Read more
December 2nd 2021
CARE paper published in Science Translational Medicine: New cell-free assay
CARE paper published in Science Translational Medicine: New cell-free assay A CARE research team developed a cell-free assay to quantify neutralizing antibody responses. Neutralizing antibody responses to SARS-CoV-2 are usually assessed using cell-based assays requiring live virus. These assays are time-consuming and necessitate additional biosafety precautions, thus limiting their clinical use. The new cell-free assay [...]
Read more
November 30th 2021
CARE paper published in Circulation: Mechanisms of SARS-CoV-2 with regards to endothelial cells
CARE paper published in Circulation: Mechanisms of SARS-CoV-2 with regards to endothelial cells The CARE scientists investigated if the coronavirus infects and damages endothelial cells directly by viral infection or indirectly via neighborhood effects, circulating mediators and immune mechanisms. Endothelial cells build a cell layer that lines blood vessels and regulates exchanges between the blood [...]
Read more
November 26th 2021
CARE paper published in iScience: CD177 is associated with coronavirus disease 2019 severity and death
CARE paper published in iScience: CD177 is associated with coronavirus disease severity In an effort to increase the understanding of SARS-CoV-2, CARE researchers found that the activation of a type of white blood cells called neutrophils could be linked to the overexpression of a protein encoded by the CD177 gene. They concluded that CD177 is [...]
Read more
November 22nd 2021
CARE paper published in Nature: HCQ use against SARS-CoV-2 infection
CARE paper published in Nature: HCQ use against SARS-CoV-2 infection CARE scientists demonstrated that there is no definitive evidence that Hydroxychloroquine (HCQ), whether alone or in combination with azithromycin, is effective for treating COVID-19. The investigation was part of CARE’s efforts to evaluate the efficacy of repurposed drugs. To learn more, read the paper in [...]
Read more
October 8th 2021
Repurposing efforts concluded
Repurposing efforts conducted The partners of the CARE consortium conducted a high throughput screening (HTS), or testing, of approximately 20,000 approved or clinically validated compounds as part of its emergency response track (pillar 1 of the research programme). The CARE research teams identified several single digit µM compounds. However, none of these were deemed beneficial [...]
Read more
October 4th 2021
CARE scientists identified a SARS-CoV-2 neutralizing antibody with activity against all known variants of concern
CARE scientists identified a SARS-CoV-2 neutralizing antibody with activity against all known variants of concern One of CARE’s approach to develop therapeutics to address the COVID-19 pandemic is the discovery of virus neutralizing antibodies. With this goal, the CARE partner Centre Hospitalier Universitaire Vaudois screened B cells from COVID-19 donors and identifyed P5C3, a highly [...]
Read more
May 31st 2021
One Year of CARE Against COVID-19
One Year of CARE Against COVID-19 / Interview Part 3 / On March 11, 2020 the novel coronavirus outbreak has been declared a pandemic. To combat the virus, multiple approaches are needed including therapeutic options that help those who are infected and those who are not able to be vaccinated or do not develop a strong immune response. In addition, [...]
Read more
May 17th 2021
One Year of CARE Against COVID-19
One Year of CARE Against COVID-19 / Interview Part 2 / On March 11, 2020 the novel coronavirus outbreak has been declared a pandemic. To combat the virus, multiple approaches are needed including therapeutic options that help those who are infected and those who are not able to be vaccinated or do not develop a strong immune response. In addition, [...]
Read more
May 3rd 2021
One Year of CARE Against COVID-19
One Year of CARE Against COVID-19 / Interview Part 1 / On March 11, 2020 the novel coronavirus outbreak has been declared a pandemic. To combat the virus, multiple approaches are needed including therapeutic options that help those who are infected and those who are not able to be vaccinated or do not develop a strong immune response. In addition, [...]
Read more
April 2nd 2021
Survey on GDPR and eConsent during the COVID-19 pandemic
Survey on Data protection and eConsent during the COVID-19 pandemic The team of task 8.3 Ethical, legal, and societal issues (ELSI) on broad spectrum anti-coronavirus therapeutics development is pleased to invite you to take part in an online survey to share your experience on key challenges related to compliance with the EU General Data Protection [...]
Read more
October 6th 2020
Mention of CARE in Le Monde
Mention of the CARE project in Le Monde newspaper The CARE project and a few of its coordinator and principal investigators (Yves Lévy, Bruno Canard, Johan Neyts) have been mentioned in an article published on Nature.com on October 6th 2021. Read the article
Read more
September 21st 2020
EMA – ITF collaboration
Innovation Task Force Leaders of the IMI CARE and SCORE consortia joined an Innovation Task Force (ITF) meeting with the European Medicines Agency (EMA) on September 21, 2020. Establishing an exchange between the consortia and the EMA at an early stage, the participants focused in this preparatory discussion on scientific and regulatory topics relevant to the development [...]
Read more
August 31st 2020
IMI Press release
CARE embarks on an unprecedented mission to get ready for coming COVID-19 waves and new coronavirus outbreaks. The world needs to prepare for a future wherein waves of COVID-19 and other coronavirus outbreaks become part of the landscape. Apart from studying the potential of existing drugs to treat COVID-19 in the short-term, the CARE consortium [...]
Read more
August 18th 2020
CARE Press release
Launch of CARE Press release “Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats” Read more Leaders of the IMI CARE and SCORE consortia joined an Innovation Task Force (ITF) meeting with the European Medicines Agency (EMA) on September 21, 2020. Establishing an exchange between the consortia and the EMA at an [...]
Read more
July 7th 2020
CARE Kick-off meeting week
Virtual meeting week A fruitful week to gather the Consortium partners and discuss the Work Packages. The coordinators reiterated that the overarching vision of CARE is to develop appropriate therapeutic agents to address the immediate patient need and to prepare use in any future outbreaks for any type of coronaviruses. The aim of this ambitious [...]
Read more
April 1st 2020
Start of the CARE project
The CARE project officially started on April 1st 2020. IMI launched the IMI-2 Call 21 on COVID on March 3, 2020, and the project was submitted on March 31, 2020. The results were known on May 11, 2020, and CARE was selected together with 7 other consortia. The CARE project started retrospectively on April 1, [...]
Read more